Off-Label Use Of Novo Drug May Harm Patients: Study

Law360, New York (April 19, 2011, 7:33 PM EDT) -- Novo Nordisk A/S' anti-bleeding drug for hemophiliacs has been increasingly used for off-label purposes such as hemorrhaging, though it is not effective and could increase the risk of blood clots, according to two studies released Tuesday.

In hospitals, off-label use of Novo's drug, called recombinant factor VIIa or NovoSeven, increased 140-fold between 2000 and 2008. The drug was mostly used to treat patients that underwent cardiovascular surgery and suffered body and brain trauma and hemorrhaging, according to the studies in the Annals of Internal Medicine....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.